Clinical trials: Cancer Stem Cells
Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus.
- Trial name
- NCT00424489
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse…
- Trial name
- NCT03605550
- Testing
- PTC596, Radiotherapy
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nationwide Children's Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477750
- Testing
- lenalidomide, melphalan, prednisone
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of…
- Trial name
- NCT06452732
- Testing
- MFC for the determination of leukemia stem cell
- Where
- 2 sites in China
- Volunteers
- 283 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancies
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second…
- Trial name
- NCT06807606
- Testing
- Drugs Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancy, Acute Leukemia in Remission
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA) expanded cord blood stem cells defined by the lack of serious infusion reactions or graft failure in patients with hematological malignancies…
- Conditions
- Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
- Trial name
- NCT03885947
- Testing
- Cord blood stem cells, Valproic Acid, Fludarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Alla Keyzner
Follicular Lymphoma
High-Dose Therapy Treatment in Patients With Follicular Lymphoma
Follicular lymphomas are a subgroup of B-cell non-Hodgkin lymphomas, accounting for 15% to 30% of newly diagnosed lymphomas.1-3 Median survival varies from 5 to 10 years depending on the prognostic factors at diagnosis and…
- Trial name
- NCT00696735
- Testing
- chemotherapy, high dose therapy and autologous stem cell transplantation
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- French Innovative Leukemia Organisation
Graft-versus-leukemia, Graft vs Host Disease
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center.
- Conditions
- Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
- Trial name
- NCT00106925
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004908
- Testing
- cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Where
- United States
- Sponsor
- Northwestern University
Acute Myelogenous Leukemia, Allogeneic Stem Cell Transplantation
Bisantrene for Relapsed /Refractory AML
Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive…
- Trial name
- NCT03820908
- Testing
- Bisantrene
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Sheba Medical Center
Multiple Myeloma
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Complete Response (CR) plus near CR rate of VAD (Vincristine, Adriamycin, Dexamethasone) induction chemotherapy followed by ASCT in patients with newly diagnosed MM was about 50% and CR plus near CR rate of PAD (Bortezomib…
- Trial name
- NCT01255514
- Testing
- high dose dexamethsone
- Where
- 8 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
- Trial name
- NCT04013685
- Testing
- Orca-T
- Where
- 21 sites in United States
- Volunteers
- 155 people
- Sponsor
- Orca Biosystems, Inc.
Recurrent Diffuse Intrinsic Pontine Glioma
Hypofractionated Radiotherapy for Recurrent DIPG
This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG).
- Trial name
- NCT03841435
- Testing
- Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Cincinnati
Non Hematologic Cancers, Metastatic Cancer
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
This is a Phase I, open-label, multicenter, dose-escalation trial of VS-5584, a PI3K/mTOR kinase inhibitor, in subjects with advanced non-hematologic malignancies or lymphoma.
- Conditions
- Non Hematologic Cancers, Metastatic Cancer, Lymphoma
- Trial name
- NCT01991938
- Testing
- VS-5584
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Verastem, Inc.
Multiple Myeloma
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients.
- Trial name
- NCT03441958
- Testing
- ECT-001 (UM171) expanded cord blood
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Aplastic Anemia, Leukemia, Myeloid, Acute
King's Invasive Aspergillosis Study II
Invasive fungal disease (IFD) is an important cause of mortality and morbidity in patients undergoing intensive chemotherapy or transplantation.
- Conditions
- Aplastic Anemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Bone Marrow Transplantation
- Trial name
- NCT02875743
- Testing
- Posaconazole
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- King's College Hospital NHS Trust
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04220008
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkin-Lymphoma
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and…
- Conditions
- Multiple Myeloma, Non-Hodgkin-Lymphoma, Hodgkin's Disease
- Trial name
- OCTET-CY (NCT01283776)
- Testing
- Cyclophosphamide
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- University of Cologne
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS
AMD3100 given in combination with busulfan, fludarabine (and thymoglobulin (ATG) for unrelated or HLA nonidentical donors) preparative regimen in patients with acute myelogenous leukemia (AML) / myelodysplastic syndromes (MDS).
- Trial name
- NCT00396968
- Testing
- AMD3100, Allogeneic Stem Cell Transplantation
- Sponsor
- Genzyme, a Sanofi Company
Kidney Cancer, Melanoma (Skin)
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00004135
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.